Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
AKBA

Akebia Therapeutics (AKBA) stock: insider trades, news & valuation

Net selling
Close · Oct 9, 2026 $0.80 -1.7% on the day -72.3% over 12 months 52-week range $0.80 – $3.17

Share price and insider trades

AKBA closeInsider buyInsider sale
01234NovDecJan 2026FebMarAprMayJunJulAugSepOctEEarnings release filed 2025-11-10EEarnings release filed 2026-01-12EEarnings release filed 2026-02-26EEarnings release filed 2026-05-07EEarnings release filed 2026-08-05Sold $62,181 on 2026-06-29 · Erik OstrowskiBought $86,588 on 2026-03-04 · John P. ButlerSold $900,774 on 2026-02-02 · Carolyn M. Rucci, Erik Ostrowski, John P. Butler, Nicholas Grund, Richard C Malabre, Steven Keith Burke
Bought, 12 months$87K
Sold, 12 months$963K
Insiders buying1
Insiders selling6

Akebia Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $87K and 6 sold $963K of AKBA stock on the open market.

AKBA insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q1 2026: $87K bought (1 trades)$87KQ1 2026: $901K sold (15 trades)Q1 2026Q2 2026: $62K sold (1 trades)Q2 2026Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026—0—0
Q2 2026—0$62K1
Q1 2026$87K1$901K15

Valuation, profit and volume

P/E (trailing)n/aSector median —
Market value— 
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit−$31KOn all tracked purchases -35.9%

Summary

Over the past 12 months, 1 Akebia Therapeutics, Inc. insider reported open-market purchases totaling $87K, while 6 insiders reported sales totaling $963K. 16 of 16 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

AKBA earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Aug 5, 2026 +3.1% None -27.7%S&P -0.4% +2.2%
May 7, 2026 +5.0% None -21.6%S&P +0.5% -19.4%
Feb 26, 2026 -19.9% Sold $901K +8.3%S&P -1.0% +2.3%
Jan 12, 2026 -10.6% None -9.2%S&P -0.0% -1.4%
Nov 10, 2025 -31.5% None -11.3%S&P +1.8% -8.3%
Aug 7, 2025 -1.7% None -9.6%S&P +0.7% -13.5%
May 8, 2025 +15.0% None +3.7%S&P +0.6% +55.7%
Mar 13, 2025 +6.0% None +17.1%S&P +0.7% -27.0%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Jul 1SEC Erik OstrowskiCFO Sell Plan 56,019616,616 held (−8%) $1.11 $62K -27.8% —
Mar 5SEC John P. ButlerCEO, President Buy 69,2703,367,064 held (+2%) $1.25 $87K -35.9% —
Feb 4SEC John P. ButlerCEO, President Sell Plan 114,8913,206,233 held (−3%) $1.39 $160K -42.4% —
Feb 4SEC John P. ButlerCEO, President Sell Plan 96,0653,321,124 held (−3%) $1.39 $134K -42.4% —
Feb 4SEC John P. ButlerCEO, President Sell Plan 83,6893,297,794 held (−2%) $1.39 $116K -42.4% —
Feb 4SEC Nicholas GrundChief Commercial Officer Sell Plan 53,585592,994 held (−8%) $1.39 $74K -42.4% —
Feb 4SEC John P. ButlerCEO, President Sell Plan 46,6603,417,189 held (−1%) $1.39 $65K -42.4% —
Feb 4SEC Richard C MalabreSvp, Chief Accounting Officer Sell Plan 36,142312,772 held (−10%) $1.39 $50K -42.4% —
Feb 4SEC Erik OstrowskiCFO Sell Plan 34,951672,635 held (−5%) $1.39 $49K -42.4% —
Feb 4SEC Nicholas GrundChief Commercial Officer Sell Plan 31,244561,750 held (−5%) $1.39 $43K -42.4% —
Feb 4SEC Carolyn M. RucciGeneral Counsel Sell Plan 27,544588,378 held (−4%) $1.39 $38K -42.4% —
Feb 4SEC Carolyn M. RucciGeneral Counsel Sell Plan 25,382615,922 held (−4%) $1.39 $35K -42.4% —
Feb 4SEC Steven Keith BurkeSvp, Chief Medical Officer Sell Plan 25,375969,133 held (−3%) $1.39 $35K -42.4% —
Feb 4SEC Steven Keith BurkeSvp, Chief Medical Officer Sell Plan 21,582994,508 held (−2%) $1.39 $30K -42.4% —
Feb 4SEC Steven Keith BurkeSvp, Chief Medical Officer Sell Plan 20,701948,432 held (−2%) $1.39 $29K -42.4% —
Feb 4SEC Carolyn M. RucciGeneral Counsel Sell Plan 16,846641,304 held (−3%) $1.39 $23K -42.4% —
Feb 4SEC Richard C MalabreSvp, Chief Accounting Officer Sell Plan 13,382299,390 held (−4%) $1.39 $19K -42.4% —

Insiders at Akebia Therapeutics, Inc.

InsiderBoughtSoldLast filingScore
John P. ButlerCEO, President $87K $474K Mar 5, 2026 —
Nicholas GrundChief Commercial Officer — $118K Feb 4, 2026 —
Erik OstrowskiCFO — $111K Jul 1, 2026 —
Carolyn M. RucciGeneral Counsel — $97K Feb 4, 2026 —
Steven Keith BurkeSvp, Chief Medical Officer — $94K Feb 4, 2026 —
Richard C MalabreSvp, Chief Accounting Officer — $69K Feb 4, 2026 —

AKBA stock: common questions

Are Akebia Therapeutics, Inc. insiders buying AKBA stock?

In the past 12 months, 1 insiders reported open-market purchases of AKBA worth $87K. The latest was CEO, President John P. Butler bought $87K of AKBA at $1.25 — first open-market purchase in our records.

Are Akebia Therapeutics, Inc. insiders selling AKBA stock?

6 insiders reported sales worth $963K over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is AKBA's 52-week range?

Over the past year AKBA has traded between $0.80 and $3.17. It last closed at $0.80 on Oct 9, 2026.